FMP
NASDAQ
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.
1.43 USD
-0.01 (-0.699%)
Valuation Date:
Apr 18, 2024 4:00 PM
Share Price on Valuation Date
$1.43
Stock Beta
2.363
Shares Outstanding
16426800